Samjin Pharmaceuticals Co., Ltd. (KRX:005500)
20,950
+200 (0.96%)
At close: Dec 5, 2025
Samjin Pharmaceuticals Revenue
In the year 2022, Samjin Pharmaceuticals had annual revenue of 274.03B KRW with 9.58% growth. Samjin Pharmaceuticals had revenue of 48.92B in the quarter ending September 30, 2013, a decrease of -1.45%.
Revenue
274.03B
Revenue Growth
+45.04%
P/S Ratio
0.94
Revenue / Employee
467.63M
Employees
586
Market Cap
256.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 274.03B | 23.96B | 9.58% |
| Dec 31, 2021 | 250.07B | 64.37B | 34.66% |
| Dec 31, 2012 | 185.70B | -16.05B | -7.96% |
| Dec 31, 2011 | 201.76B | 1.35B | 0.67% |
| Dec 31, 2010 | 200.41B | 35.02B | 21.18% |
| Dec 31, 2009 | Pro | Pro | Pro |
| Dec 31, 2008 | Pro | Pro | Pro |
| Dec 31, 2007 | Pro | Pro | Pro |
| Dec 31, 2006 | Pro | Pro | Pro |
| Dec 31, 2005 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |